Cargando…
Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
Targeting EGFR, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), brings lights to the treatment of non-small cell lung cancer (NSCLC). Although T790M mutation responded as one of the main reasons of acquired resistance, still 15% of the resistance patients can't be expla...
Autores principales: | Li, Guangda, Ma, Yunfei, Yu, Mingwei, Li, Xiaoxiao, Chen, Xinjie, Gao, Yu, Cheng, Peiyu, Zhang, Ganlin, Wang, Xiaomin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317531/ https://www.ncbi.nlm.nih.gov/pubmed/34335945 http://dx.doi.org/10.7150/jca.56506 |
Ejemplares similares
-
Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013) -
Identification of hub genes and small molecule therapeutic drugs related to breast cancer with comprehensive bioinformatics analysis
por: Hao, Mingqian, et al.
Publicado: (2020) -
Identification of hub genes and small-molecule compounds in medulloblastoma by integrated bioinformatic analyses
por: Liu, Zhendong, et al.
Publicado: (2020) -
Clinical characteristics and prognostic analysis of Lung Cancer patients with Hypercoagulability: A single-center, retrospective, real-world study
por: Ma, Yunfei, et al.
Publicado: (2021) -
Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)